Mayne And Mithra Receive Australian Nextstellis Approval
Launch Expected In Mid-2022 After TGA Endorses Estetrol/Drospirenone Contraceptive
Executive Summary
Mayne Pharma and Mithra have revealed launch plans in Australia for their Nextstellis oral contraceptive that combines the novel estrogen estetrol with drospirenone, following approval by the TGA.
You may also be interested in...
Three Not A Magic Number For Mayne With Another NuvaRing CRL
Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.
Multiple Molecules See UK Prices More Than Double In December
WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.
Hikma Buys Teligent Assets To Expand Into Canada
Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.